Results 131 to 140 of about 35,641 (272)

Techniques for subretinal injections in animals

Veterinary Ophthalmology, Volume 28, Issue 2, Page 506-518, March 2025.
Abstract Subretinal injections are not commonly performed during clinical treatment of animals but are frequently used in laboratory animal models to assess therapeutic efficacy and safety of gene and cell therapy products. Veterinary ophthalmologists are often employed to perform the injections in the laboratory animal setting, due to knowledge of ...
Ryan F. Boyd, Simon M. Petersen‐Jones
wiley   +1 more source

Clinical descriptive and long‐term outcome of melanocytic uveal lesions in young dogs: 40 cases (45 eyes) including 13 cases of sector iridectomy

Veterinary Ophthalmology, Volume 28, Issue 2, Page 371-385, March 2025.
Abstract Purpose To describe the clinical features surgical technique, early and long‐term outcome with or without surgery, and histopathological findings of melanocytic anterior uveal lesions in young dogs. Methods Medical records of dogs at a guide dog facility removed from training due to a pigmented iris lesion were reviewed from 2014 to 2021 ...
Valerie Liliane Dufour, Julie A. Cohen, Charles‐Antoine Assenmacher, Dolores M. Holle, Amy C. Durham, Gustavo D. Aguirre, Keiko Miyadera   +6 more
wiley   +1 more source

Acute endothelial failure after cosmetic iris implants (NewIris®)

Clinical Ophthalmology, 2011
Maria Garcia-Pous1, Patricia Udaondo2, Salvador Garcia-Delpech2, David Salom1, Manuel Díaz-Llopis21Faculty of Medicine, University of Valencia, Valencia, Spain; 2Ophthalmology Department, Hospital Universitario La Fe, Valencia, SpainAbstract ...
Garcia-Pous M, Udaondo P, Garcia-Delpech S, Salom D, Díaz-Llopis M   +4 more
doaj  

Reconstruction of deep and perforating corneal defects in dogs—A review (Part II/III): Biomaterials and keratoprosthesis

Veterinary Ophthalmology, Volume 28, Issue 2, Page 532-542, March 2025.
Abstract The surgical reconstruction of severe corneal ulcers is a common and crucial component of the clinical practice of veterinary ophthalmology. Numerous surgical techniques are used in dogs for corneal reconstruction, and these techniques may be categorized by the material used to repair the corneal lesion.
Eric C. Ledbetter, Rick F. Sanchez, Marta Leiva Repiso   +2 more
wiley   +1 more source

Physiological cerebrospinal fluid interactions between brain and eye structures are altered after long‐duration spaceflight

Experimental Physiology, EarlyView.
Abstract Long‐duration spaceflight represents an extreme challenge, triggering adaptive responses including spaceflight‐associated neuro‐ocular syndrome, characterized by diminished visual acuity and ocular changes, which is a significant health risk for Mars missions.
Ge Tang, Steven Jillings, Ben Jeurissen, Elena Tomilovskaya, Inna Nosikova, Alexandra Ryabova, Ekaterina Pechenkova, Viktor Petrovichev, Ilya Rukavishnikov, Stefan Sunaert, Paul M. Parizel, Lyudmila Makovskaya, Valentin Sinitsyn, Jan Sijbers, Jitka Annen, Steven Laureys, Angelique Van Ombergen, Seyed‐Ahmad Ahmadi, Floris L. Wuyts, Peter zu Eulenburg   +19 more
wiley   +1 more source

Tuberculous Endophthalmitis With Phthisis Bulbi: A Diagnostic Delay Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Tuberculous endophthalmitis should be prioritized in differential diagnosis for unexplained endophthalmitis in TB‐endemic regions; early systemic evaluation, timely pars plana vitrectomy, and adjunctive corticosteroids are crucial to prevent phthisis bulbi, though evidence for some interventions remains limited.
Yanchen Chen, Shengnan Li, Xin Chen, Ningpu Liu, Dongjing Liu   +4 more
wiley   +1 more source

Congenital aniridia: European COST action ANIRIDIA‐NET guidelines for diagnosis, management and care

Acta Ophthalmologica, Volume 104, Issue 3, Page 267-279, May 2026.
Abstract Congenital aniridia is a rare ocular disorder affecting the majority of eye structures and can be associated with systemic manifestations. The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign. Other ocular comorbidities are associated
Davide Romano, Vito Romano, Alejandra Daruich, Giulio Ferrari, Matthieu Robert, Francesco Semeraro, Neil Lagali, Dominique Bremond‐Gignac, the ANIRIDIA‐NET Clinical Guidelines Working Group, Miriam Barbany, Claus Cursiefen, Stefano Ferrari, Francisco Figueiredo, Christina Grupcheva, Jesper Hjortdal, Elke Kreps, Erlend Landsend, Laura Mauring, Hilde Pedersen, Nora Szentmáry, Bogumil Wowra, the Aniridia‐Europa and Geniris Working Group, Sophie Valleix, Juan Álvarez de Toledo, James Lauderdale, Tor Paaske Utheim, Paolo Rama   +26 more
wiley   +1 more source

Characterising PRPF31‐associated retinal dystrophy: Clinical insights from baseline data in a natural history study

Acta Ophthalmologica, Volume 104, Issue 3, Page e317-e328, May 2026.
Abstract Purpose To characterise the baseline clinical features and genotypes of adults with pre‐mRNA processing factor 31 (PRPF31)‐associated retinal dystrophy (RD) enrolled in a prospective, multicentre 4‐year natural history study, and to explore correlations between selected baseline parameters.
Kathrine Olaussen Eriksen, Jon Roger Eidet, Ulrika Kjellström, Jacopo Baldesi, Ragnheidur Bragadóttir, Leonardo Colombo, Josephine Prener Holtan   +6 more
wiley   +1 more source

Blindness and prognostic factors after trabeculectomy with mitomycin C in patients with open‐angle glaucoma with long‐term follow‐up

Acta Ophthalmologica, Volume 104, Issue 3, Page e232-e238, May 2026.
Abstract Purpose To determine the long‐term blindness rate and related prognostic factors in eyes with open‐angle glaucoma after trabeculectomy using adjunctive mitomycin C (MMC). Methods The retrospective cohort study included 714 eyes from 714 patients with open angle glaucoma who underwent trabeculectomy using MMC.
Masato Matsuo, Akira Sawada, Taishi Miyase, Masayuki Inuzuka, Masaomi Kubota, Tetsuya Yamamoto   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source